Literature DB >> 12928641

Insertion of a left ventricular assist device in patients without thorough transplant evaluations: a worthwhile risk?

Mathew Williams1, Jennifer Casher, Neel Joshi, Todd Hankinson, Michelle Warren, Mehmet Oz, Yoshifumi Naka, Donna Mancini.   

Abstract

OBJECTIVES: Patients in acute cardiogenic shock may require placement of left ventricular assist devices before undergoing standard pretransplant evaluations. This practice raises ethical and logistic concerns and has led us to investigate the short- and long-term outcomes for this patient population. Methods and results We examined our adult bridge-to-transplant left ventricular assist device population over a 6-year period to characterize those patients with acute cardiogenic shock who received left ventricular assist devices on an emergency basis (ie, placement of a device within 24 hours of being listed for cardiac transplantation). Outcomes before and after transplant were compared with those of candidates with nonemergency evaluations by Kaplan-Meier survival curves and the Fisher exact test where appropriate. Of the 115 patients who required left ventricular assist device support, 73 (63%) patients required emergency placement; 70% of these patients survived to transplant compared with 83% of those with nonurgent device implantation (not statistically significant). Posttransplant survival curves were similar for patients with emergency device placement and those with nonurgent placement (not statistically significant). Twenty-two patients having emergency device placement did not undergo heart transplantation because of multisystem organ failure (14), device support withdrawal from irreversible neurologic injury (4), device or technical problems (2), and left ventricular assist device explant due to myocardial recovery (2).
CONCLUSIONS: At our institution, the majority of left ventricular assist devices are placed on an emergency basis. Few of these patients require discontinuation of device support due to undetected conditions during abbreviated preoperative evaluation. Survival before and after transplant is comparable with those of patients who undergo nonurgent left ventricular assist device placement or medical therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12928641     DOI: 10.1016/s0022-5223(03)00056-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Disseminated malignancy after extracorporeal life support and left ventricular assist device, diagnosed by left ventricular apical core biopsy.

Authors:  Tine E Philipsen; Tom Vermeulen; Viviane M Conraads; Inez E Rodrigus
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07-30

Review 2.  Recombinant activated factor VII (Novo7) in patients with ventricular assist devices: case report and review of the current literature.

Authors:  Daniel Heise; Anselm Bräuer; Michael Quintel
Journal:  J Cardiothorac Surg       Date:  2007-10-26       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.